BioSpace News Archive

Profound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes

Profound Medical Corp. is pleased to announce the voting results from its Annual Meeting of Shareholders that was held

May 19, 2021
·
5 min read
Drug Development

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL)

May 19, 2021
·
14 min read
Genetown

Moderna to Host Fourth Annual Science Day on May 27, 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it will host its virtual Science Day for analysts and investors at 8:00 a.m. ET on Thursday, May 27.

May 19, 2021
·
2 min read
Pharm Country

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.

May 19, 2021
·
5 min read
Drug Development

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Rubius Therapeutics, Inc. announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting cell program, RTX-321, at the American Society of Clinical Oncology Annual Meeting being held virtually from June 4-8, 2021.

May 19, 2021
·
5 min read
Bio NC

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

G1 Therapeutics, Inc., a commercial-stage oncology company, announced upcoming data presentations at the American Society of Clinical Oncology annual meeting, being held virtually June 4th through 8th.

May 19, 2021
·
2 min read
Biotech Bay

Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual MeetingManagement to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting beginning on June 4,2021.

May 19, 2021
·
6 min read
Genetown

Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021

Cullinan Oncology, Inc., an oncology company seeking to drive shareholder returns by focusing on the patient, announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4th, 2021 at 10:30 am ET.

May 19, 2021
·
5 min read
BioMidwest

Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

New data from across Eli Lilly and Company’s oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.

May 19, 2021
·
62 min read
Pharm Country

Breast Cancer Treatments Do Not Increase Risk of Covid-19 Infection or Death

Cancer drugs capable of weakening the body’s immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows.

May 19, 2021
·
4 min read